Tyra Biosciences, Inc.

NASDAQ:TYRA

14.25 (USD) • At close December 23, 2024
Bedrijfsnaam Tyra Biosciences, Inc.
Symbool TYRA
Munteenheid USD
Prijs 14.25
Beurswaarde 753,423,506
Dividendpercentage 0%
52-weken bereik 11.24 - 29.6
Industrie Biotechnology
Sector Healthcare
CEO Dr. Todd Harris Ph.D.
Website https://www.tyra.bio

An error occurred while fetching data.

Over Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing

Vergelijkbare Aandelen

Esperion Therapeutics, Inc. logo

Esperion Therapeutics, Inc.

ESPR

2.24 USD

Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc.

GLUE

7.14 USD

Belite Bio, Inc logo

Belite Bio, Inc

BLTE

62.82 USD

Regencell Bioscience Holdings Limited logo

Regencell Bioscience Holdings Limited

RGC

4.77 USD

Arcellx, Inc. logo

Arcellx, Inc.

ACLX

76.79 USD

Inotiv, Inc. logo

Inotiv, Inc.

NOTV

3.94 USD

Kodiak Sciences Inc. logo

Kodiak Sciences Inc.

KOD

9.25 USD

MeiraGTx Holdings plc logo

MeiraGTx Holdings plc

MGTX

6.09 USD

Viridian Therapeutics, Inc. logo

Viridian Therapeutics, Inc.

VRDN

19.67 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)